ArticleEye and vision (London, England)2026
One-year outcomes of combined phacoemulsification and goniosynechialysis in primary angle-closure glaucoma with cataracts: a multicenter prospective study.
Article in Eye and vision (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThis study aimed to observe the safety and effectiveness of combined phacoemulsification and goniosynechialysis (PEI-GSL) in patients with primary angle-closure glaucoma (PACG) and coexisting cataracts.
methodsThis multicenter prospective study enrolled 289 consecutive patients with PACG and cataracts who were treated using PEI-GSL between November 1, 2022 and March 12, 2024. All patients underwent comprehensive ocular evaluations at baseline, at 1 week, and at 1, 3, 6, and 12 months postoperatively. Complete success was defined as achieving an intraocular pressure (IOP) of 6-18 mmHg without antiglaucoma medications or reoperation. Qualified success was similarly defined but allowed antiglaucoma medications.
resultsAmong patients with PACG, 237 (82.0%) of 289 completed a 12-month follow-up. The baseline IOP decreased from 22.9 ± 10.2 to 14.0 ± 3.1 mmHg at 12 months, and the number of antiglaucoma medications declined from 2.08 ± 1.23 to 0.14 ± 0.52. The complete and qualified success rates were 80.6% and 88.3%, respectively. Postoperative complications occurred in 49 (17.0%) patients; while 3 (1.0%) patients underwent yttrium-aluminum-garnet (YAG) laser capsulotomy and 6 (2.1%) required glaucoma surgery. Multivariate Cox regression analysis revealed that the anterior chamber depth (P = 0.044) and axial length (P = 0.050) were positively associated with qualified success. The complete and qualified success rates among patients with advanced PACG were 78.2% and 87.9%, respectively.
conclusionWe demonstrated that PEI-GSL is an effective and safe treatment for patients with PACG and coexisting cataracts, even in advanced stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.